




RealRate

# PHARMACEUTICAL 2018

## Actinium Pharmaceuticals Inc. Rank 263 of 342





RealRate

# PHARMACEUTICAL 2018

## Actinium Pharmaceuticals Inc. Rank 263 of 342



The relative strengths and weaknesses of Actinium Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Actinium Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 72% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	17,839
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,666
Liabilities, Non-Current	0
Other Assets	441
Other Compr. Net Income	0
Other Expenses	56
Other Liabilities	0
Other Net Income	310
Other Revenues	0
Property and Equipment	57
Research and Development	17,700
Selling, General and Administrative Expense	9,155

Output Variable	Value in 1000 USD
Assets	18,337
Liabilities	4,666
Expenses	26,911
Revenues	0
Stockholders Equity	13,671
Net Income	-26,601
Comprehensive Net Income	-26,601
Economic Capital Ratio	-27%